Amendment #1693 to H5500

Maintaining Patient Access to Care

Representatives Decker of Cambridge and Consalvo of Boston move to amend the bill in section 2, in item 1108-5200, in line 39, by inserting after “means” the following: “; provided further, that the commission shall maintain coverage for glucagon-like peptide-1 (GLP-1) receptor agonist medications for the treatment of obesity for all members who do not have an FDA-approved comorbidity”; and moves to further amend the bill in item 4000-0300, in line 160, by inserting after “2027” the following: “; provided further, that the department shall maintain coverage for glucagon-like peptide-1 (GLP-1) receptor agonist medications for the treatment of obesity”.

Additional co-sponsor(s) added to Amendment #1693 to H5500

Maintaining Patient Access to Care